STRIDES ARCOLAB RECEIVES US FDA APPROVAL FOR TOPOTECAN INJECTION

*Product to be launched immediately through Pfizer*

**August 29, 2012:** Onco Therapies Limited, a wholly owned subsidiary of Strides Arcolab Limited (Strides) today announced that it has received ANDA approval for “**Topotecan Hydrochloride Injection 4 mg (base), packaged in single dose vials**”.

According to IMS data, the US market for generic Topotecan is approximately USD 51 Million.

Topotecan is part of the Oncology portfolio licensed to Pfizer for the US market and the product is available for immediate launch.

**About Topotecan**

**Topotecan** is a chemotherapy drug usually given to treat ovarian cancer, small-cell lung cancer and advanced cervical cancer.

**About Agila Specialties**

Agila, Specialties business of Strides Arcolab is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 9 world-class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila’s marketing network covers 70 countries and it has partnerships with some of the world’s leading pharmaceutical companies for both developed and emerging markets.
**About Strides Arcolab**

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

Additional information is available at the company’s website at www.stridesarco.com.

For further information, please contact:

<table>
<thead>
<tr>
<th><strong>Strides</strong></th>
<th><strong>PR Consultancy</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Mr. V.S. Iyer, CEO - Agila  +91 80 6784 0111</td>
<td>Corporate Voice</td>
</tr>
<tr>
<td>Mr. Ajay Singh : +91 80 6784 0813 Mr. Kannan N : +91 98450 54745 (Investors)</td>
<td>Mahesh Nair, +91 9880376648 <a href="mailto:maheshn@corvoshandwick.co.in">maheshn@corvoshandwick.co.in</a></td>
</tr>
<tr>
<td></td>
<td>Kaveri Mandanna, +91 90089 59697 <a href="mailto:kaveri@corvoshandwick.co.in">kaveri@corvoshandwick.co.in</a></td>
</tr>
</tbody>
</table>